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Purpose: Following Robotic-Assisted Radical Prostatectomy (RARP) patients routinely have penile pain and urethral
discomfort secondary to an indwelling urethral catheter. Our objective was to assess the effect of dorsal penile
nerve block with bupivacaine on urethral catheter-related pain after RARP.
Methods: From 2012–2013, 140 patients with organ-confined prostate cancer were enrolled in an IRB approved
double-blinded, randomized control trial comparing a dorsal penile nerve block of bupivacaine versus placebo after
RARP performed by a single-surgeon. Patients were asked to complete questionnaires using the Wong-Bakers FACES
Pain Rating scale while hospitalized and for 9 days post-operatively, until the catheter was removed. The primary
end-points were: catheter-related discomfort, abdominal (incisional) pain, and bladder spasm-related discomfort.
Secondary end-points included narcotic and other analgesic usage.
Results: 120 patients were randomized to placebo vs. bupivacaine dorsal penile nerve bock. The two arms (n = 56
bupivacaine and n = 60 placebo) did not differ in preoperative, perioperative, or pathological results. There was no
difference in narcotic utilization between the two cohorts. Abdominal pain was slightly lower in the bupivacaine arm
at 6 hours compared to the placebo arm, but there was no difference in abdominal pain at other time points, and
there were no differences in reported catheter-related discomfort or bladder spasm-associated discomfort at any
of the measured time points.
Conclusions: The data does not support the routine use of a dorsal penile nerve block with bupivacaine
following RARP.
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Over the past decade, robot-assisted radical prostatectomy
(RARP) has surpassed open radical prostatectomy as
the most common surgical treatment for prostate cancer.
Greater than 75% of radical prostatectomies in the United
States and Europe are now performed with the da Vinci
Surgical System (Intuitive Surgical, Sunnyvale, CA) (Mottrie
and Ficarra 2010). The rapid adoption of RARP has
resulted, in part, due to a shallower learning curve as* Correspondence: aw2616@columbia.edu
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in any medium, provided the original work is pwell clinical benefits including decreased blood loss,
transfusion requirement, duration of hospital stay, and
perioperative complication rates, without sacrificing onco-
logic outcomes (Ficarra et al. 2009; Barocas et al. 2010).
RARP is also associated with decreased postoperative pain
at the incision sites (Ficarra et al. 2009). Patients require
postoperative bladder drainage, most commonly via ur-
ethral catheterization, which is associated with significant
patient-reported physical limitations and discomfort (Lepor
et al. 2001).
Urinary catheter-related discomfort has been described
as a burning sensation spreading from the suprapubic area
to the penis with an urge to void thought to be due to
friction between the catheter and the urothelium. Thisis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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muscarinic receptors; the first line treatment is anticholin-
ergic medications similar to the treatment for overactive
bladder. However, these treatments are not without side
effects, most notably dry mouth, blurred vision, and facial
flushing (Kaufman et al. 2007). Targeting this discomfort
early is essential, because these effects often first occur in
the recovery unit, and are very concerning for patients and
their families as it often exacerbates the incisional pain
from surgery. Intravenous or oral narcotic medication have
been shown to be effective in the prevention and treatment
catheter-related discomfort, but these agents cause sedation
after the operation, delayed bowel function, and may pro-
long hospitalization (American Society of Anesthesiologists
Task Force on Acute Pain Management 2012).
Patients are routinely managed with a variety of pain med-
ications including opiates, non-steroidal anti-inflammatory
drugs, and acetaminophen while in the hospital. Upon
discharge, many patients are continued on a similar cock-
tail of orally available medications while convalescing at
home. Parenteral ketorolac has been investigated by many
groups internationally and it is debated on its efficacy in
preventing or decreasing catheter discomfort (Agarwal
et al. 2006a). At our intuition, ketorolac is given at the dis-
cretion of the anesthesiologist, and is primarily used to
minimize the amount of narcotic medication administered
postoperatively. Currently there is no specific countermeas-
ure for catheter-related discomfort. In the event of signifi-
cant catheter-related bother, patients are simply reassured.
Bupivacaine is a Food and Drug Administration (FDA)-
approved local anesthetic of the amide group used for per-
ipheral nerve blocks for many urologic and general surgical
procedures (Babst and Gilling 1978; Leone et al. 2008;
Gauntlett 2003). The dorsal penile nerve block has been
extensively studied in the setting of neonatal circumcision
(Bacon 1977), and has been shown to be safe and effective
(Brady-Fryer et al. 2004). There have been no studies in
the literature evaluating the ability of a dorsal penile nerve
block to alleviate catheter-related discomfort. Furthermore,
it is not known whether diminution of catheter-related
discomfort can affect the overall perception of postoper-
ative pain following radical prostatectomy. Anecdotal
evidence using a bupivacaine dorsal penile nerve block
following endoscopic treatment of urethral stricture disease,
with subsequent long-term urethral catheter drainage, has
had beneficial results. We investigate the use of bupiva-
caine dorsal penile nerve block to control post-operative
pain following RARP to add further techniques to the pain
management armamentarium.
Materials and methods
After obtaining the approval of the Columbia Univer-
sity Medical Center Institutional Review Board, we
conducted a prospective, randomized, double-blinded,placebo-controlled study comparing bupivacaine (Mar-
caine, 5 mg/mL, Hospira Inc., Lake Forest, IL) dorsal
penile nerve block versus normal saline injection at the
conclusion of RARP for localized prostate cancer.
Between January 2012 and May 2013, 140 patients were
initially enrolled in this study. We excluded those with
chronic pain conditions, patients currently on narcotics,
patients with history of indwelling-catheterization, ureth-
ral or prostatic surgery, patients allergic to bupivacaine or
other local anesthetics, patients with bleeding disorders,
abnormal genital anatomy or liver abnormalities. All stand-
ard FDA contraindications and warnings for bupivacaine
were considered amongst our exclusion criteria. All patients
signed informed consent before participating and were
blinded to the randomization scheme.
All patients underwent standard RARP with bilateral
pelvic lymph node dissection performed by a single sur-
geon (KKB). The camera trocar was placed just to the left
of the umbilicus and was extended at the conclusion of
the procedure to allow for specimen extraction. This site
was then closed with interrupted figure-of-eight sutures.
All skin incisions were infiltrated with 10–20 mL of 0.25%
bupivacaine. After the urethral anastomosis was complete,
but prior to the placement of the final 18-French catheter,
the patient received a dorsal penile nerve block using
bupivacaine or an injection of saline based on their
randomization assignment. The study-coordinator, who
was the only team member who knew the randomization
results, handed the surgeon a syringe containing either
20 mL of bupivacaine 0.25% or 20 mL of saline (placebo)
for the penile block. The nerve block was performed by
anesthetizing the right and left dorsal penile nerves, the
deepest divisions of the pudendal nerve (Gauntlett 2003).
The syringe was aspirated to ensure that no vascular
structure was entered. A total of 20 mL was injected
subcutaneously in the sub-pubic space at the base of the
penis, cephalad to the dorsal penile vessels, as well as cir-
cumferentially at the time of skin closure. A 20 mL syringe
attached to a 21-gauge needle was used for all injections.
After the operation, blinded research assistants ad-
ministered questionnaires related to the patient’s pain
from three domains: abdominal (incisional) pain, urethral
catheter-related pain, and bladder spasm-related discom-
fort. The questionnaires were based on the Wong-Baker
FACES Pain Rating visual analog scale (VAS), which rates
pain on a 0–10 scale (Price et al. 1983). The questionnaires
were administered once the patients arrived in the post-
operative recovery unit at 30 minutes, 90 minutes, 6 hours,
12 hours, 18 hours, and 24 hours post-operatively. All
patients were discharged on the first post-operative day.
After discharge, the patients were asked to fill out the
same questionnaire regarding their pain parameters on a
daily basis for 9 days until their follow-up appointment
and catheter removal.











Age (range) 60.8 (47-72) 61.2 (46-75) 0.78
BMI (range) 27.8 (18.8-40.0) 27.1 (20.1-38.5) 0.28
Diabetes (%) 4 (6.4%) 6 (10.3%) 0.74
PVD (%) 1 (1.6%) 1 (1.7%) 0.96
History of narcotics use (%) 0 (0%) 1 (3.1%) 0.48
PSA (range, ng/mL) 6.2 (0.9-24.0) 6.6 (0.9-25.7) 0.54
Operative time
(mean ± SD, minutes)
186 ± 79 166 ± 80 0.18
Preoperative Gleason score 0.84
6 19 (32%) 22 (39%)
7 34 (58%) 28 (49%)
≥8 6 (10%) 7 (12%)
Intra-operative medications
Opiates (mean ± SD,
mg MED)
94.1 ± 39.6 89.3 ± 38.2 0.51
Ketorolac usage 38% 34% 0.63
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while in the hospital was collected via the aid of an elec-
tronic medication dispensation and recording system.
Medications that were recorded included all opiate an-
algesics, non-steroidal anti-inflammatory medications
(in the form of intravenous ketorolac) and anticholinergic
medication (in the form of oral oxybutynin 5 mg).
Our standard post-operative pain regimen for patients
following RARP is the following: acetaminophen 325 mg
PO 1 tab every 4–6 hours for pain score 1–3 on a 10-
point scale, acetaminophen/codeine 325 mg/30 mg PO 1
tab every 4–6 hours for pain score 4–6 on a 10-point
scale, acetaminophen/codeine 325 mg/30 mg PO 2 tabs
every 4- 6 hours for pain score 7–10 on a 10-point scale,
and hydromorphone 1 mg IV every 3 hours for break-
through pain. No patients are prescribed standing opiate
medication. Patients are given standing post-operative
ketorolac IV (15 mg or 30 mg) every 6–8 hours if they
have normal renal function and no operative contraindica-
tion. For those who experienced bothersome bladder
spasms, anticholinergic medications are given on a PRN
basis in the form of oxybutynin 5 mg PO every 8 hours.
On discharge, patients are prescribed acetaminophen/
codeine 325 mg/30 mg PO 1–2 tab every 4–6 hours on
a PRN basis. Once at home, in addition to filling out
pain questionnaires, they were also asked to self-report
opiate usage on a daily basis. While the above analgesicFigure 1 CONSORT flow diagram.












Anticholinergic, Usage (%) 28% 25% 0.73
Anticholinergic (# doses
of oxybutynin 5 mg)
0.8 ± 2.1 0.5 ± 0.9 0.21
Opiates (mean ± SD, mg of MED) 41.2 ± 45.5 31.5 ± 24.6 0.16
IV Ketorolac Usage 73% 84% 0.17
IV Ketorolac (mean ± SD, mg) 49.5 ± 34.8 57.3 ± 32.5 0.62
Post-discharge medications
Opiates (mean ± SD, mg of MED) 68.5 ± 64.3 47.3 ± 51.1 0.05
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ing RARP, the physicians taking care of the patient were
at liberty to deviate from these standards if deemed
necessary.
To facilitate analysis, all doses of opiates taken by the
patient were converted to oral morphine sulfate equiva-
lents doses (MED) (Svendsen et al. 2011). Using pain scores
from similar studies in the urologic literature we assumed a
VAS difference of 1.5 (on a scale of 1–10) between placebo
and bupivacaine with a standard deviation of 1.3 (pooled
standard deviation of 0.9 to 2.1) and a power of 99%, the
sample size need for each group was 50. We estimated a
dropout rate of 20% and we planned to enroll 60 patients.
Student’s t-test was used to compare continuous variables
and chi-square analysis was used to compare categoricalFigure 2 Post-Operative Opiate Utilization Following RARP with Placedistributions between the treatment groups. A post-hoc
modified bonferroni correction was used to account for
alpha inflation due to multiple primary end-points. Analysis
was performed with SPSS version 21.0 (IBM, Armonk, NY)
with p < 0.05 defined as significant.
Results
140 patients were initially enrolled into the study. 2
patients were excluded due to current narcotic usage
(n = 1) and bleeding disorder (n = 1). 18 patients withdrew
prior to randomization, leaving 120 patients who were
randomized in a 1:1 fashion to either a placebo (saline)
injection or bupivacaine dorsal penile nerve block. After
randomization, no patients were lost to follow-up in the
placebo group (n = 60) and four were lost in the bupiva-
caine group (n = 56), leaving 116 patients for final analysis
(Figure 1). Mean patient age was 61 (range 46–75). Demo-
graphics and clinical characteristics of the cohorts were
comparable; there was no difference with respect to age,
body mass index (BMI), incidence of diabetes or peripheral
vascular disease (PVD), preoperative PSA, stage, or patho-
logic Gleason score between the two arms (Table 1).
The two arms did not differ in the amount of opiate
medications or ketorolac usage or dose given intraop-
eratively (Table 1). The mean ± SD intraoperative opiate
amount given to the patients in the placebo arm was
94.1 ± 39.6 mg of MED and 89.3 ± 38.2 mg of MED in
the bupivacaine arm (p = 0.51).
When analyzing the use of analgesic medication while
in the hospital, there was no difference in the incidence
of utilizing periurethral lidocaine jelly for catheter-related
discomfort, anticholinergic medication (given as oxybutyninPlacebo Injection Arm
Bupivicaine Injection Arm










Figure 3 Post-Operative Pain or Discomfort Measured by
Questionnaire in Three Domains (Based on a 10-Point Wong-Baker
FACES Pain Rating Scale). a. Post-Operative Abdominal (Incisional)
Pain Following RARP with Placebo vs. Bupivacaine Dorsal Penile Nerve
Block. b. Post-Operative Urethral Catheter-Related Discomfort Following
RARP with Placebo vs. Bupivacaine Dorsal Penile Nerve Block. c.
Post-Operative Bladder Spasm-Related Discomfort Following RARP
with Placebo vs. Bupivacaine Dorsal Penile Nerve Block.
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utilization or dose given. The mean ± SD inpatient opiate
usage was 41.2 ± 45.5 mg for the placebo arm and 31.5 ±
24.6 mg for the bupivacaine arm (p = 0.16, Table 2). The
outpatient opiate usage following discharge was calculated
at the time of follow-up for catheter removal was de-
creased in the bupivacaine cohort (mean ± SD 68.5 ±
64.3 mg of MED) compared to the placebo cohort
(47.3 ± 51.1 mg of MED), but this did not reach statistical
significance with a p-value of 0.05 (Table 2, Figure 2).
When considering the subjective, patient-reported pain
parameters, there was a decreased reported sensation of
abdominal (incisional) pain 6 hours after the operation in
the bupivacaine arm (mean ± SD score of 2.0 ± 1.9 out of
10-point scale) compared to the placebo arm (mean ± SD
score of 3.7 ± 2.4) with a p = 0.004 (Figure 3a). There were
no significant differences in reported abdominal pain at
the other time points examined, or at any time points
examined when patients were asked to report the pain
or discomfort related to the urethral catheter (Figure 3b)
or related to bladder spasm (Figure 3c).
No adverse events were reported by any patients receiv-
ing either saline or bupivacaine blocks, including local and
allergic reactions.
Discussion
Robot-assisted radical prostatectomy is associated with
shorter duration of hospital stay and post-operative pain,
but catheter-related discomfort remains a burden to pa-
tients (Ficarra et al. 2009). In designing this study, we
hypothesized that the administration of bupivacaine as a
regional dorsal penile nerve block would reduce post-
operative pain associated with an indwelling catheter.
The half-life of bupivacaine is 2.7 hours in adults, so the
anesthetic effect of the penile block is in effect through
the very immediate post-operative recovery period (Babst
and Gilling 1978). The study was also designed to investi-
gate whether patients that received penile nerve block
would report lower pain scores during the entire duration
of their recovery period, not only during the first few hours
post-surgery, as pain at one site has been hypothesized to
result in sensitization and lowering of pain thresholds at
other sites and after the noxious stimuli has been removed
(Latremoliere and Woolf 2009).
Catheter-related discomfort is a common fear discussed
in pre-operative evaluation and a significant source of
morbidity expressed during post-operative care following
radical prostatectomy. Binhas et al. found that up to 63%
of men who had an indwelling catheter post-operatively
reported significant discomfort within the first hour; with
men with larger catheter sizes experiencing severe discom-
fort two-times greater than those with smaller catheters
(>18-French vs. <18-French) (Binhas et al. 2011). Addition-
ally, Lepor at al. found that in men undergoing open radical
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tations caused by the presence of an indwelling catheter
(Lepor et al. 2001).
Pain management following radical prostatectomy has
largely relied on the administration of analgesic medica-
tion, particularly opiates. Several studies suggest that
pain following radical prostatectomy is best controlled
with ketorolac, given its efficacy for pain control, earlier
return of bowel function, and association with shorter
hospital stay (Kaufman et al. 2007; See et al. 1995; Kay
et al. 2002). However, these studies did not distinguish
between incisional and catheter-related pain. Further-
more, the effects of ketorolac on platelet function in the
post-operative period have yet to be fully elucidated. In
practice, ketorolac is often augmented with narcotics used
to control breakthrough pain (Mazzocca et al. 2013).
The adverse effects of opioid analgesia are significant,
and include nausea, pruritus, respiratory depression, and
decreased intestinal motility. Decreasing post-operative
opioid requirement would likely hasten the return of bowel
function and shorten convalescence. Anticholinergic medi-
cations have shown to be somewhat effective at lessening
post-operative opioid requirement and urinary catheter
discomfort when compared to placebo (p < 0.05), but
subjects still reported significant discomfort (Agarwal
et al. 2006b; Tauzin-Fin et al. 2007).
Suprapubic catheters are associated with less pain and
urgency than urethral catheterization following RARP
(Krane et al. 2009; Orikasa et al. 2012), however many
patients may object to the creation of a cystostomy for
the purpose of pain control. Intravesical administration
of the local anesthetic ropivicaine during RARP has been
investigated, however no significant difference in reported
pain scores was seen when compared to placebo (Fuller
et al. 2013).
Overall, our data does not show a statistically significant
difference between placebo and bupivacaine penile nerve
block after RARP in the post-operative pain parameters,
with the exception of the abdominal (incisional) pain at the
6 hour time-point following RARP, which was statistically
significantly lower in the bupivacaine arm as compared
to the placebo arm. There were also no differences in
inpatient or outpatient opiate analgesic utilization between
the two arms.
Despite the prospective, randomized, double-blinded,
placebo-controlled study design, there are limitations
to the study. It was calculated that 100 patients were
required to detect a 25% decrease in reported pain
scores. There may have been an overestimation of the
effect of the nerve block, in which case, the study may
be underpowered to detect statistically significant dif-
ferences in pain scores. This theory is supported by
the fact that the pain scores in both arms were fairly
low. Although prospectively collected, the pain-ratingsscales are still vulnerable to biases inherent in all
questionnaires.
Conclusions
Compared to placebo, the use of a bupivacaine dorsal
penile nerve block does result in decreased self-reported
abdominal (incisional) pain 6 hours following a RARP,
however this decrease does not persist over time, nor are
there significant differences in opiate utilization, urethral
catheter-related discomfort, or bladder spasm-related dis-
comfort. Overall, the study does not support the routine
usage of bupivacaine dorsal penile block following RARP.
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